What is Lantern Pharma?
Lantern Pharma is at the forefront of revolutionizing cancer drug development through its proprietary RADR® platform. This advanced technology integrates artificial intelligence, machine learning, genomics, and extensive oncology data to expedite the identification of patient populations likely to respond to specific therapies. By optimizing clinical trials and developing targeted treatments, Lantern Pharma aims to accelerate the delivery of precision oncology solutions, thereby reducing the inherent costs, risks, and timelines associated with bringing novel cancer therapies to market.
How much funding has Lantern Pharma raised?
Lantern Pharma has raised a total of $8.1M across 2 funding rounds:
Series A
$3.7M
Stock/Share Issuance
$4.4M
Series A (2017): $3.7M with participation from GPG Ventures and Bios Partners
Stock/Share Issuance (2026): $4.4M, investors not publicly disclosed
Key Investors in Lantern Pharma
GPG Ventures
GPG Ventures is a Dallas-based venture capital firm with extensive operational and financial experience, specializing in investment opportunities within the medical technology sector. They focus on providing strategic solutions and financial backing to innovative start-ups and growth-stage companies.
Bios Partners
Bios Partners is a venture capital firm dedicated to advancing biotech innovations, with a particular emphasis on compelling scientific opportunities often overlooked in the Central U.S. They invest in clinical-stage companies developing novel therapeutics for various medical conditions.
What's next for Lantern Pharma?
The recent major strategic investment positions Lantern Pharma to further accelerate its pipeline of targeted cancer drug candidates. This capital will likely fuel expanded research and development efforts, enhance clinical trial operations, and potentially support strategic partnerships. As a clinical-stage biotechnology firm operating in a rapidly evolving field, Lantern Pharma's continued focus on data-driven drug discovery and development, supported by this significant financing, suggests a strategic push towards achieving key regulatory milestones and commercialization objectives.
See full Lantern Pharma company page
